Emcure Pharmaceuticals shareholders and shareholding pattern
NSE: EMCUREBSE: 544210Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,770.40down ₹12.20 (0.68%)BSE ₹1,768.35
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,782.60.
52-week range of traded prices to 23 Oct 2026
₹1,306.50Low, 4 Nov 2025₹2,100.70High, 18 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹33,586 Cr266th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 33.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 5 May 2026
- 6.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.20%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 21.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 25.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 5 May 2026
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,41,41252.9% delivered
Who owns Emcure Pharmaceuticals, filing by filing
Per cent of the company's shares. Every filing on record, from Sep 2024; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters77.82%
- Foreign institutions4.94%
- Indian institutions8.49%
- Individuals and others8.75%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Sep 2024Filed 18 Oct | Dec 2024Filed 21 Jan | Mar 2025Filed 21 Apr | Jun 2025Filed 21 Jul | Sep 2025Filed 20 Oct | Dec 2025Filed 20 Jan | Mar 2026Filed 17 Apr | Jun 2026Filed 21 Jul | Sep 2026Filed 19 Oct |
|---|---|---|---|---|---|---|---|---|---|
| 78.08% | 77.94% | 77.92% | 77.91% | 77.88% | 77.87% | 77.87% | 77.83% | 77.82% | |
| Indian promoters | 77.85% | 77.71% | 77.69% | 77.68% | 77.66% | 77.65% | 77.64% | 77.60% | 77.59% |
| Foreign promoters | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% | 0.23% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 21.92% | 22.06% | 22.08% | 22.09% | 22.12% | 22.13% | 22.13% | 22.17% | 22.18% |
| Promoter shares pledgedShare of the promoters' own shares | 0.00% | 0.00% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Shares in issue | 18,90,98,347 | 18,94,31,847 | 18,94,83,347 | 18,95,08,347 | 18,95,64,847 | 18,95,72,547 | 18,95,89,547 | 18,96,80,147 | 18,97,10,647 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 17,26,13,207 | 16,97,23,277 | 3,79,59,271 | 3,79,59,271 | 3,79,59,271 | 3,79,59,271 | – | – | – |
| Promoters' shares locked in | 14,76,49,282 | 14,76,49,282 | 3,79,59,271 | 3,79,59,271 | 3,79,59,271 | 3,79,59,271 | – | – | – |
Pledged is the share of the promoters' own shares given to lenders as security. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Emcure Pharmaceuticals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Satish R Mehta, 39.74%. The filing names 21 more members with no shares.Promoter buying and selling
| Holder | |||
|---|---|---|---|
| Satish R MehtaIndividuals and Hindu undivided families | 39.74% | 7,53,96,748 | 0.00% |
| Everest Trust (Shares held by Sanjay Rajanikant Mehta with Sonali Sanjay Mehta, as trustees)Indian companies, trusts and others | 7.65% | 1,45,20,000 | 0.00% |
| Unity Trust (Shares held by Sunil Rajanikant Mehta with Kamini Sunil Mehta, as trustees)Indian companies, trusts and others | 7.65% | 1,45,08,000 | 0.00% |
| Samit Satish MehtaIndividuals and Hindu undivided families | 7.14% | 1,35,37,632 | 0.00% |
| Bhavana Satish MehtaIndividuals and Hindu undivided families | 4.70% | 89,16,888 | 0.00% |
| Namita Vikas ThaparIndividuals and Hindu undivided families | 2.67% | 50,71,200 | 0.00% |
| Pushpa Rajnikant MehtaIndividuals and Hindu undivided families | 2.05% | 38,86,052 | 0.00% |
| Sanjay Rajanikant MehtaIndividuals and Hindu undivided families | 1.95% | 37,04,028 | 0.00% |
| Sunil Rajanikant MehtaIndividuals and Hindu undivided families | 1.50% | 28,47,012 | 0.00% |
| Kamini Sunil MehtaIndividuals and Hindu undivided families | 0.88% | 16,64,960 | 0.00% |
| Niraj Sunil MehtaIndividuals and Hindu undivided families | 0.55% | 10,43,100 | 0.00% |
| Rutav Sunil MehtaIndividuals and Hindu undivided families | 0.55% | 10,45,124 | 0.00% |
Pledged is the share of the holder's own shares pledged to a lender.
Largest public holders of Emcure Pharmaceuticals, filing by filing
Per cent, on the same shares as the split above.Mutual funds holding Emcure Pharmaceuticals
| Holder | Sep 2024Filed 18 Oct | Dec 2024Filed 21 Jan | Mar 2025Filed 21 Apr | Jun 2025Filed 21 Jul | Sep 2025Filed 20 Oct | Dec 2025Filed 20 Jan | Mar 2026Filed 17 Apr | Jun 2026Filed 21 Jul | Sep 2026Filed 19 Oct |
|---|---|---|---|---|---|---|---|---|---|
| Government Pension Fund GlobalForeign portfolio investors, category I | – | – | – | – | – | – | – | 1.05% | 1.05% |
| Hdfc Life Insurance Company LimitedInsurance companies | – | – | – | – | – | – | – | 1.03% | – |
| BC Investments IV LimitedForeign companies | 8.69% | 8.68% | 8.68% | 8.67% | 6.30% | 3.87% | 3.87% | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. Mutual funds are left out here: each fund's holding is on the Mutual funds tab, from its own portfolio. A dash is a filing that did not name the holder, which includes holding under one per cent.